

**APPOINTMENT OF COMPANY SECRETARY**

**MELBOURNE (AUSTRALIA) 29 October 2021:** Invion Limited (ASX: IVX) ("Invion" or the "Company") wishes to announce the appointment of Ms Claire Newstead-Sinclair as Company Secretary, replacing Ms Melanie Leydin effective 1 November 2021. Ms Newstead-Sinclair is a Chartered Accountant at the Company Secretarial and Accounting firm Leydin Freyer with extensive ASX biotechnology experience across statutory reporting, compliance and corporate governance. Ms Leydin will continue in her role as company CFO.

**Investor and Media enquiries:**

Thian Chew (Chairman &amp; CEO)

T: +61 3 8618 6843

E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

Brendon Lau (Investor &amp; Media Relations)

M: +61 409 341 613

E: [brendon.lau@inviongroup.com](mailto:brendon.lau@inviongroup.com)**About Invion**

Invion is a life-science company that is undertaking the global research and development of Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights to the Photosoft™ technology for all cancer indications and Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX). This announcement was approved for release by Thian Chew, Chairman of the Board.

**About Photodynamic Therapy (PDT)**

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission.

For personal use only